TGFβ and EGF synergistically induce a more invasive phenotype of epithelial ovarian cancer cells

Biochemical and Biophysical Research Communications

Volumn 401, Issue 3, 2010, Pages 376-381

  Xu, Zhihua ^a   Jiang, Yanyan ^a   Steed, Helen ^a   Davidge, Sandra ^a   Fu, YangXin ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

EGF; Epithelial ovarian cancer; Epithelial mesenchymal transition; Slug; Snail; TGF

Indexed keywords

EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CONTROLLED STUDY; DENSITOMETRY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; METASTASIS; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ZYMOGRAPHY;

CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; EPIDERMAL GROWTH FACTOR; EPITHELIUM; FEMALE; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MATRIX METALLOPROTEINASE 2; MESODERM; OVARIAN NEOPLASMS; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA;

GASTROPODA;

EID: 77958153789     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.09.059     Document Type: Article

References (38)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58:71-96.
2. Levanon K., Crum C., Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J. Clin. Oncol. 2008, 26:5284-5293.
3. Auersperg N., Wong A.S., Choi K.C., Kang S.K., Leung P.C. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. 2001, 22:255-288.
4. Yap T.A., Carden C.P., Kaye S.B. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat. Rev. Cancer 2009, 9:167-181.
5. Cannistra S.A. Cancer of the ovary. N. Engl. J. Med. 2004, 351:2519-2529.
6. Ahmed N., Thompson E.W., Quinn M.A. Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. J. Cell. Physiol. 2007, 213:581-588.
7. Vergara D., Merlot B., Lucot J.P., Collinet P., Vinatier D., Fournier I., Salzet M. Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett. 2010, 291:59-66.
8. Thiery J.P., Sleeman J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 2006, 7:131-142.
9. Elloul S., Elstrand M.B., Nesland J.M., Trope C.G., Kvalheim G., Goldberg I., Reich R., Davidson B. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 2005, 103:1631-1643.
10. Kurrey N.K., Amit K., Bapat S.A. Snail and Slug are major determinants of ovarian cancer invasiveness at the transcription level. Gynecol. Oncol. 2005, 97:155-165.
11. Blechschmidt K., Sassen S., Schmalfeldt B., Schuster T., Hofler H., Becker K.F. The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. Br. J. Cancer 2008, 98:489-495.
12. Jin H., Yu Y., Zhang T., Zhou X., Zhou J., Jia L., Wu Y., Zhou B.P., Feng Y. Snail is critical for tumor growth and metastasis of ovarian carcinoma. Int. J. Cancer 2010, 126:2102-2111.
13. Massague J. TGFbeta in cancer. Cell 2008, 134:215-230.
14. Attisano L., Wrana J.L. Signal transduction by the TGF-beta superfamily. Science 2002, 296:1646-1647.
15. Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-584.
16. Henriksen R., Gobl A., Wilander E., Oberg K., Miyazono K., Funa K. Expression and prognostic significance of TGF-beta isotypes, latent TGF-beta 1 binding protein, TGF-beta type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms. Lab. Invest. 1995, 73:213-220.
17. Higashi T., Sasagawa T., Inoue M., Oka R., Shuangying L., Saijoh K. Overexpression of latent transforming growth factor-beta 1 (TGF-beta 1) binding protein 1 (LTBP-1) in association with TGF-beta 1 in ovarian carcinoma. Jpn. J. Cancer Res. 2001, 92:506-515.
18. Santin A.D., Bellone S., Ravaggi A., Roman J., Smith C.V., Pecorelli S., Cannon M.J., Parham G.P. Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG 2001, 108:804-808.
19. Bartlett J.M., Langdon S.P., Simpson B.J., Stewart M., Katsaros D., Sismondi P., Love S., Scott W.N., Williams A.R., Lessells A.M., Macleod K.G., Smyth J.F., Miller W.R. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br. J. Cancer 1996, 73:301-306.
20. Niikura H., Sasano H., Sato S., Yajima A. Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors. Int. J. Gynecol. Pathol. 1997, 16:60-68.
21. Mendelsohn J., Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 2003, 21:2787-2799.
22. Wilson K.J., Gilmore J.L., Foley J., Lemmon M.A., Riese D.J. Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol. Ther. 2009, 122:1-8.
23. El-Rayes B.F., LoRusso P.M. Targeting the epidermal growth factor receptor. Br. J. Cancer 2004, 91:418-424.
24. Omerovic J., Laude A.J., Prior I.A. Ras proteins: paradigms for compartmentalised and isoform-specific signalling. Cell. Mol. Life Sci. 2007, 64:2575-2589.
25. Do T.V., Kubba L.A., Du H., Sturgis C.D., Woodruff T.K. Transforming growth factor-beta1, transforming growth factor-beta2, and transforming growth factor-beta3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition. Mol. Cancer Res. 2008, 6:695-705.
26. Lim R., Ahmed N., Borregaard N., Riley C., Wafai R., Thompson E.W., Quinn M.A., Rice G.E. Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int. J. Cancer 2007, 120:2426-2434.
27. Colomiere M., Ward A.C., Riley C., Trenerry M.K., Cameron-Smith D., Findlay J., Ackland L., Ahmed N. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br. J. Cancer 2009, 100:134-144.
28. Colomiere M., Findlay J., Ackland L., Ahmed N. Epidermal growth factor-induced ovarian carcinoma cell migration is associated with JAK2/STAT3 signals and changes in the abundance and localization of alpha6beta1 integrin. Int. J. Biochem. Cell Biol. 2009, 41:1034-1045.
29. Fu Y., Sies H., Lei X.G. Opposite roles of selenium-dependent glutathione peroxidase-1 in superoxide generator diquat- and peroxynitrite-induced apoptosis and signaling. J. Biol. Chem. 2001, 276:43004-43009.
30. Fu Y., Chang A., Chang L., Niessen K., Eapen S., Setiadi A., Karsan A. Differential regulation of transforming growth factor beta signaling pathways by notch in human endothelial cells. J. Biol. Chem. 2009, 284:19452-19462.
31. Fernandez-Patron C., Radomski M.W., Davidge S.T. Role of matrix metalloproteinase-2 in thrombin-induced vasorelaxation of rat mesenteric arteries. Am. J. Physiol. Heart Circ. Physiol. 2000, 278:H1473-H1479.
32. Peinado H., Olmeda D., Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat. Rev. Cancer 2007, 7:415-428.
33. Ramos J.W. The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int. J. Biochem. Cell Biol. 2008, 40:2707-2719.
34. Lin S.W., Lee M.T., Ke F.C., Lee P.P., Huang C.J., Ip M.M., Chen L., Hwang J.J. TGFbeta1 stimulates the secretion of matrix metalloproteinase 2 (MMP2) and the invasive behavior in human ovarian cancer cells, which is suppressed by MMP inhibitor BB3103. Clin. Exp. Metastasis 2000, 18:493-499.
35. Itoh Y., Nagase H. Matrix metalloproteinases in cancer. Essays Biochem. 2002, 38:21-36.
36. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2:161-174.
37. Palayekar M.J., Herzog T.J. The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer. Int. J. Gynecol. Cancer 2008, 18:879-890.
38. Yingling J.M., Blanchard K.L., Sawyer J.S. Development of TGF-beta signalling inhibitors for cancer therapy. Nat. Rev. Drug Discov. 2004, 3:1011-1022.